Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Eur J Med Res. 2010 Jan 29;15(1):13-9. doi: 10.1186/2047-783x-15-1-13.
In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy. However, data for patients with advanced multiple myeloma is rare.
In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range: 1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids.
Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively.
In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.
在多发性骨髓瘤患者中，苯达莫司汀单药治疗作为一线和二线治疗均具有疗效。然而，针对晚期多发性骨髓瘤患者的数据较为罕见。
通过病例研究，我们在本机构中确定了 39 名复发性或难治性多发性骨髓瘤患者，这些患者接受了苯达莫司汀作为挽救性治疗。在先前接受中位数为 2 线治疗（范围：1-5）后，患者接受了中位数为 3（范围：1-10）个周期的苯达莫司汀治疗。苯达莫司汀剂量为每月周期的第 1 天和第 2 天 80-150mg。39%的患者接受了苯达莫司汀单药治疗，而 61%的患者接受了同时使用皮质类固醇治疗。
毒性为轻度至中度。缓解率如下：3%vgPR、33%PR、18%MR、26%SD 和 20%PD。中位无进展生存期和总生存期分别为 7 个月和 17 个月。
总之，在晚期多发性骨髓瘤患者中，苯达莫司汀具有疗效且毒性较轻。因此，应在进一步的临床试验中探讨苯达莫司汀在多发性骨髓瘤患者中的作用。
